On December 30, the company announced the submission of the NDA for Sotagliflozin for the treatment of heart failure in Type2 Diabetes patients. Following the
This year, biotech companies on the stock exchange have skyrocketed. This is no surprise since biotech firms are the leaders in the battle against the
At Stocktstelegraph.com, we are committed to helping investors make smart and profitable decisions. Our goal is to make investing easier and more accessible to everyone. We strive to provide the best and most reliable market information, news and analysis to ensure that our readers can make informed decisions.